RSSReview

Use of Repetitive Transcranial Magnetic Stimulation in Child Psychiatry

Use of Repetitive Transcranial Magnetic Stimulation in Child Psychiatry

| April 1, 2022

by Anca Maria Bejenaru, MD, and Narpinder Kaur Malhi, MD Drs. Bejenaru and Malhi are with the Department of Psychiatry and Behavioral Health, Christiana Care in Wilmington, Delaware. Funding: No funding was provided for this study. Disclosures: The authors have no conflicts of interest relevant to the content of this article. Innov Clin Neurosci. 2022;19(4–6):11–22. […]

Continue Reading

Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis

Comparative Analysis of Treatment Outcomes in Patients with Neuromyelitis Optica Spectrum Disorder Treated with Rituximab, Azathioprine, and Mycophenolate Mofetil: A Systematic Review and Meta-analysis

| April 1, 2022

by Christy Magdalena, MD, MRes; Audrey Clarissa, MD, MRes; and Nathania Sutandi, MD, MRes All authors are with Faculty of Medicine, Universitas Indonesia, Cipto Mangunkusumo National Referral Hospital in Jakarta, Indonesia. Funding: No funding was provided for this study. Disclosures: The authors have no conflicts of interest relevant to the article. Innov Clin Neurosci. 2022;19(4–6):51–64. Abstract […]

Continue Reading

Implementing Digital Technologies in Clinical Trials: Lessons Learned

Implementing Digital Technologies in Clinical Trials: Lessons Learned

| April 1, 2022

by Georgia Mitsi, PhD; Todd Grinnell, BA; Suzanne Giordano, PhD; Thomas Goodin, Phd; Shahin Sanjar, PhD; Elizabeth Marble, BS; and Andrei Pikalov, MD, PhD All authors are with Sunovion Pharmaceuticals Inc. in Marlborough, Massachusetts. Funding: The studies described herein and medical writing support were supported by funding from Sunovion Pharmaceuticals Inc.   Disclosures: All authors […]

Continue Reading

The Role of Transcranial Magnetic Stimulation as a Surrogate Marker of Disease Activity in Patients with Multiple Sclerosis: A Literature Review

The Role of Transcranial Magnetic Stimulation as a Surrogate Marker of Disease Activity in Patients with Multiple Sclerosis: A Literature Review

| January 1, 2022

by Muhannad M. Alsharidah, MBBS; Mohammad Uzair, BS; Sarah S. Alseneidi, MBBS; Afnan A. Alkharan, MBBS; Reem Fahd Bunyan, MBBS; and Shahid Bashir, PhD Drs. Alsharidah and Alseneidi are with the College of Medicine, King Saud University in Riyadh, Saudi Arabia. Mr. Uzair is with the Department of Biological Sciences, Faculty of Basic and Applied […]

Continue Reading

Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC)

Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC)

| January 1, 2022

by Leslie Citrome, MD, MPH; Anissa Abi-Dargham, MD; Robert M. Bilder, PhD; Ruth A. Duffy, PhD; Boadie W. Dunlop, MD; Philip D. Harvey, PhD; Diego A. Pizzagalli, PhD; Carol A. Tamminga, MD; Roger S. McIntyre, MD; and John M. Kane, MD Dr. Citrome is with New York Medical College in Valhalla, New York. Dr. Abi-Dargham is with […]

Continue Reading

Pimavanserin in the Treatment of Parkinson’s Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials

Pimavanserin in the Treatment of Parkinson’s Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials

| January 1, 2022

by Zeeshan Mansuri, MD, MPH; Abhishek Reddy, MD; Ramu Vadukapuram, MD; Chintan Trivedi, MD, MPH; and Amy Amara, MD, PhD  Dr. Mansuri is with the Department of Psychiatry, Boston Children’s Hospital/Harvard Medical School in Boston, Massachusetts. Dr. Reddy is with the Department of Psychiatry, Virginia Tech Carilion School of Medicine in Roanoke, Virginia. Dr. Vadukapuram is with […]

Continue Reading

Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials

Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials

| January 1, 2022

by Erica A. Smith, PhD; William P. Horan, PhD; Dominique Demolle, PhD; Peter Schueler, MD; Dong-Jing Fu, MD, PhD; Ariana E. Anderson, PhD; Joseph Geraci, MSc, PhD; Florence Butlen-Ducuing, MD, PhD; Jasmine Link, MS; Ni A. Khin, MD; Robert Morlock, PhD; and Larry D. Alphs, MD, PhD Drs. Smith and Demolle are with Cognivia in Mont St. […]

Continue Reading

Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization

Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization

| October 1, 2021

by Joan Busner, PhD; Gahan Pandina, PhD; Silvia Zaragoza domingo PhD; Anna-Karin Berger PhD; Maria T. Acosta, MD; Nahome Fisseha, PharmD; Joseph Horrigan, MD; Jelena Ivkovic, MD; William Jacobson, PhD; Dennis Revicki, PhD; and Victoria Villalta-Gil, PhD, MSc All authors are members of the ISCTM Working Group for Rare Disease/Orphan Drug Development; Drs. Busner and Pandina […]

Continue Reading

Blood–Brain Barrier: COVID-19, Pandemics, and Cytokine Norms

Blood–Brain Barrier: COVID-19, Pandemics, and Cytokine Norms

| January 1, 2021

by Atmaram Yarlagadda, MD; Samuel L. Preston, DO;  Rachel P. Jeyadhas, MD; Adam Edward Lang, PharmD;  Rasha Hammamieh, PhD; And Anita H. Clayton, MD Dr. Yarlagadda is the Installation Director of Psychological Health at McDonald Army Health Center in Fort Eustis, Virginia. Dr. Preston is with Uniformed Services University of Health Sciences in Bethesda, Maryland. […]

Continue Reading